Our mission is to provide 7 billion people with access to high-quality medicine. But access is about more than stocking pharmacy shelves.
It’s all about driving and championing policy. Policies that improve access. Policies designed to change restrictive laws that limit access. And polices that promote one global standard of quality for all medicines.
Why so passionate about policy?
Because we believe in breaking down the barriers between safe, effective and affordable medicines and the people all over the world who need them.
Driving Biogeneric Access
Biogenerics are generic equivalents of biologics—expensive medicines for diseases like multiple sclerosis, rheumatoid arthritis, diabetes and cancer. We promote effective biogeneric approval pathways that drive interchangeability, maximise patient access to more affordable, high-quality biologics and reduce healthcare spending. In South Africa Mylan is working closely with key stakeholders to ensure we drive access in this sphere.
Raising Anaphylaxis Awareness
Food allergy is the most common cause of anaphylaxis, a life-threatening allergic reaction that demands immediate treatment with adrenaline. Although the prevelance of anaphylaxis in South Africa is unknown, severe allergies are on the increase and affect South Africans of all race, gender and age. Mylan is actively raising awareness on anaphylaxis and the importance of being prepared to minimise unnecessary death from this life threatening condition. Through partnerships with key stakeholders including patient advocacy groups and The Allergy Society of South Africa (ALLSA), Mylan aims to ensure patients are always PREPARED. To find out more visit www.epipen.co.za
Approximately 35 million people in the developing world are infected with HIV, the virus that causes AIDS. Twenty-eight million need treatment. Less than a quarter of them receive it. We advocate for funding to focus on proven methods of treatment and prevention. In South Africa Mylan is one of the leading suppliers of ARV's to the South African National Department of Health, supporting the governments initiative to increase the number of patients on triple therapy FDC regimens, to simplify treatment and improve patient adherance.